Revenue
0 USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
Avenue Therapeutics, Inc.
EDGARAnnual consolidated revenue for 2025: about USD 1.404M, using the latest reported figures. The previous period, 2024, was about USD 0.
Latest quarter
- Cash and cash equivalents
- 1.94 million USD Source
Exact value
1942000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 3.29 million shares Source
Exact value
3294967 shares
Reported share-count change
3.50% · 111 thousand shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-07.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2025-12-31
- Operating income: 7 of 11 periods available· newest 2025-12-31
- Net income: 5 of 11 periods available· newest 2025-12-31
- Operating cash flow: 7 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 2 of 11 periods available· newest 2025-12-31
- Total liabilities: 2 of 11 periods available· newest 2025-12-31
- current assets: No compatible figures in this window
- Current liabilities: 2 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 2 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+USD 1.4 millionPrior period
USD 0
–
Current period
USD 1.4 million
–
Exact inputs and evidence
1404000 − 0 = 1404000 USD
0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source1404000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 8.74 millionPrior period
−USD 11.65 million
–
Current period
−USD 2.91 million
–
Exact inputs and evidence
-2909000 − -11652000 = 8743000 USD
-11652000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-2909000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 7.19 millionPrior period
−USD 9.03 million
–
Current period
−USD 1.83 million
–
Exact inputs and evidence
-1833000 − -9026000 = 7193000 USD
-9026000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-1833000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 1.4 million 100% of revenue
- Operating costs Derived USD 4.49 million 320% of revenue
- Operating income −USD 3.08 million −220% of revenue
- Tax, interest and other Derived −USD 174,000 −12% of revenue
- Net income −USD 2.91 million −207% of revenue
Cash
- Operating cash flow −USD 1.83 million −131% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2024 Not shown: operating income or net income is not reported.
- 2025 Operating loss: operating costs were 320% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | 0 | 11283000 Derived | -11283000 | 369000 Derived | -11652000 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 1404000 | 4487000 Derived | -3083000 | -174000 Derived | -2909000 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 1.4M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Revenue | 0 |
|
| 2025 | Revenue | 1404000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Year over year | No prior comparable period |
|
| 2025 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -219.6% 2025
Net margin -207.2% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Operating margin | Not reported |
|
| 2025 | Operating margin | -219.6% |
|
| 2024 | Net margin | Not reported |
|
| 2025 | Net margin | -207.2% |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -1.8M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Operating cash flow | -9026000 |
|
| 2025 | Operating cash flow | -1833000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
37.5% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Liabilities / assets | 30.5% |
|
| 2025 | Liabilities / assets | 37.5% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024-12-31 | Current assets / current liabilities | Not reported |
|
| 2025-12-31 | Current assets / current liabilities | Not reported |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | −USD 3.18 million Exact valueExact value: -3177000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.63 million Exact valueExact value: -1632000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2017-01-01 – 2017-12-31 | −USD 12.26 million Exact valueExact value: -12258000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 6.8 million Exact valueExact value: -6802000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | −USD 21.55 million Exact valueExact value: -21548000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 18.22 million Exact valueExact value: -18216000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | Unavailable Not reported for this period. | −USD 7.6 million Exact valueExact value: -7596000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | Unavailable Not reported for this period. | −USD 9.45 million Exact valueExact value: -9451000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 11.65 million Exact valueExact value: -11652000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 9.03 million Exact valueExact value: -9026000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 2.91 million Exact valueExact value: -2909000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.83 million Exact valueExact value: -1833000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
51 filings · 2,015 latest values · 2,015 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001644963, 1644963, ATXI, edgar:1644963
Also known as AVENUE THERAPEUTICS, INC., AVENUE THERAPEUTICS, INC., Avenue Therapeutics, Inc.